96783-68-5

Usage

Uses

Used in Pharmaceutical Industry:
N-(3-Aminomethyl-phenyl)-acetamide is used as an intermediate for the synthesis of various medications, contributing to the development of new drugs with potential therapeutic benefits.
Used in Drug Development:
N-(3-AMINOMETHYL-PHENYL)-ACETAMIDE is utilized in drug development due to its pharmacological properties, which allow it to interact with biological systems and potentially lead to the creation of novel therapeutic agents.
Used in Research:
N-(3-Aminomethyl-phenyl)-acetamide is employed in research settings to study its interactions with biological systems and explore its potential applications in medicine and pharmacology.

Upstream product

• 903556-11-6 tert-butyl 3-acetamidobenzylcarbamate 
• 58202-84-9 N-(3-cyanophenyl)acetamide 

Downstream Products

• 918811-11-7 Ethyl 2-(3-acetamidobenzylamino)acetate 
• 1114978-92-5 (E)-N-(3-acetamidobenzyl)-5-(2-(4-methoxybenzylidene)hydrazinyl)-3-methyl-1H-pyrazole-4-carboxamide 
• 1333728-05-4 C₁₉H₂₅N₃O₃ 
• 1355772-06-3 C₁₈H₂₂N₄O₂ 
• 1600521-00-3 C₁₇H₂₁N₃O₃ 
• 1581755-39-6 (R)-N-(3-acetamidobenzyl)-1-(1-(naphthalen-1-yl)ethyl)-piperidine-4-carboxamide 
• 59755-25-8 3-acetylaminobenzaldehyde 

Relevant academic research and scientific papers

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

The COVID-19 pandemic has been disastrous to society and effective drugs are urgently needed. The papain-like protease domain (PLpro) of SARS-CoV-2 (SCoV2) is indispensable for viral replication and represents a putative target for pharmacological intervention. In this work, we describe the development of a potent and selective SCoV2 PLpro inhibitor, 19. The inhibitor not only effectively blocks substrate cleavage and immunosuppressive function imparted by PLpro, but also markedly mitigates SCoV2 replication in human cells, with a submicromolar IC50. We further present a convenient and sensitive activity probe, 7, and complementary assays to readily evaluate SCoV2 PLpro inhibitors in vitro or in cells. In addition, we disclose the co-crystal structure of SCoV2 PLpro in complex with a prototype inhibitor, which illuminates their detailed binding mode. Overall, these findings provide promising leads and important tools for drug discovery aiming to target SCoV2 PLpro.

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)